- Home
- /
- Treatment
- /
- Page 114
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
5,5′,5″-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride | Pancreatic Cancer | Now Pharm AG;241, route d'Arlon, L-1150; | August 20, 2003 | |
Eculizumab | Hemoglobinuria | Alexion Pharmaceuticals, Inc.;352 Knotter Drive;Cheshire, Connecticut, 06410 | August 20, 2003 | |
Debrase | Debridement of acute, deep dermal burns in hospitalized patients | MediWound, Ltd.;42 Hayarkon Street, Industrial Zone; | August 20, 2003 | |
(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid | Patients undergoing solid organ transplantation | Pfizer Global Research and Development;50 Pequot Avenue;New London, Connecticut, 06320 | August 19, 2003 | |
Dehydroepiandrosterone (DHEA) | Replacement therapy in individuals with adrenal insufficiency | Paladin Labs, Inc.;6111 Royalmount Avenue, Suite 102, Montreal;Quebec H4P 2T4 | August 19, 2003 | |
Cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation | DiGeorge syndrome | Enzyvant Therapeutics GmbH;Viaduktstrasse 8, CH-4051 Basel; | August 15, 2003 | |
2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate | Cystic fibrosis | Inologic, Inc.;101 Elliott Ave., West;Seattle, Washington, 98119 | August 15, 2003 | |
Mx-dnG1 or Rexin-G retroviral vector | Pancreatic Cancer | Epeius Biotechnologies Corporation;345 Pioneer Drive, 1803W;Glendale, California, 91203 | August 15, 2003 | |
Combretastatin A4 Phosphate | Medullary thyroid cancer | Mateon Therapeutics, Inc.;701 Gateway Boulevard, Suite 210;South San Francisco, California, 94080 | July 23, 2003 | |
Erlotinib Hydrochloride | Malignant gliomas | Genentech, Inc;1 DNA Way;South San Francisco, California, 94080 | July 18, 2003 | |
Cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanolic acid) | Bile Acid Synthesis | Asklepion Pharmaceuticals, LLC;729 East Pratt Street, Suite 360;Baltimore, MD, 21202 | July 18, 2003 | |
Chimeric monoclonal antibody to CD30 (anti-CD30 antibody) | Hodgkin’s disease | Seattle Genetics, Inc;21823 30th Drive, Southeast;Bothell, Washington, 98021 | July 18, 2003 | |
Conjugated bile acids | Short bowel syndrome | Jarrow Formulas, Inc.;1824 S. Robertson Blvd.;Los Angeles, California, 90035 | July 18, 2003 | |
Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab | For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation | Cubist Pharmaceuticals;65 Hayden Avenue;Lexington, Massachusetts, 02421 | July 15, 2003 | |
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide | Tardive dyskinesia | Phase 2 Discovery, Inc.;3130 Highland Ave., Third Floor;Cincinnati, Ohio, 45219 | July 3, 2003 | |
Ferric hexacyanoferrate (II) “Prussian Blue” | Patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium | Degussa AG;Weissfrauenstr.9, D-60287;Frankfurt | June 26, 2003 | |
Arsenic trioxide | Hepatocellular Carcinoma | Teva Branded Pharmaceutical Products R&D;, Inc.;41 Moores Road, P. O. Box 4011;Frazer, Pennsylvania, 19355 | June 13, 2003 | |
Diphenylcyclopenone | Alopecia areata | Lloyd E. King, Jr.;1900 Patterson Street, Suite 104;Nashville, Tennessee, 37203 | June 13, 2003 | |
Diferuloylmethane | Cystic fibrosis | Allertein Therapeutics, LLC;640 Sasco Hill Road;Fairfield, Connecticut, 06824 | June 13, 2003 | |
Protaxel | Ovarian cancer | Biophysica, Inc.;2159 Avenida de la Playa, Suite B;La Jolla, California, 92037 | May 21, 2003 | |
Factor XIII [A2] homodimer, recombinant DNA origin | Congenital FXIII deficiency | Novo Nordisk Pharmaceuticals, INc.;100 College Road West;Princeton, New Jersey, 08540 | May 21, 2003 | |
Defibrotide | Hepatic venoocclusive disease | Jazz Pharmaceuticals, Inc.;3180 Porter Dr.;Palo Alto, California, 94304 | May 21, 2003 | |
Infliximab | Sarcoidosis | Centocor, Inc.;200 Great Valley Parkway;Malvern, Pennsylvania, 19355 | May 21, 2003 | |
Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201) | Pancreatic Cancer | Avaant Pharmaceuticals India Ltd.;3rd Floor, Neelkanth Commercial Centre, Mumbai - 400 099; | May 21, 2003 | |
Arsenic trioxide | Chronic lymphocytic leukemia | Teva Branded Pharmaceutical Products R&D;, Inc.;41 Moores Road, P.O. Box 4011;Frazer, Pennsylvania, 19355 | May 13, 2003 |